Primary results from the phase III SHINE trial demonstrated that first-line treatment with ibrutinib combined with bendamustine/rituximab and rituximab maintenance achieves a substantial prolongation of progression-free survival in elderly patients with mantle cell lymphoma, according to a presentation at the 2022 ASCO Annual Meeting by lead investigator Michael Wang, MD, Professor of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, Houston.1
In an analysis presented at the 2022 ASCO Annual Meeting and simultaneously reported in the Journal of Clinical Oncology, Michael Wang, MD, and colleagues provided data from the 3-year follow-up of the pivotal ZUMA-2 trial of the chimeric antigen receptor T-cell therapy brexucabtagene autoleucel in patients with relapsed or refractory mantle cell lymphoma.
On May 28, the FDA granted accelerated approval to the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. Tisagenlecleucel is now FDA-approved in three indications and remains the only CAR T-cell therapy approved in both adult and pediatric settings.
A study published by Jackson et al in Cancer Discovery investigated the reasons for decreased remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor (CAR) T-cell therapy.
Natural killer (NK) cells derived from donated umbilical cord blood, activated with a novel bispecific antibody targeting CD16A and CD30 known as AFM13, have yielded responses in patients with pretreated and refractory CD30-positive lymphoma. The overall response rate was 89%, with 53% complete remissions, in patients with relapsed or refractory CD30-positive lymphoma, according to results from an investigator-initiated phase I/II trial reported at the American Association for Cancer Research (AACR) Annual Meeting 2022.1 All patients treated at the recommended dose for phase II responded, for an overall response rate of 100%, with a 62% complete remission rate in this cohort. Tolerability was reported to be excellent, with none of the treatment-related adverse events associated with chimeric antigen receptor (CAR) T-cell therapy.